Produção Nacional
Revisado por pares
α-Lipoic Acid as Adjunctive Treatment for Schizophrenia
2017; Lippincott Williams & Wilkins; Volume: 37; Issue: 6 Linguagem: Inglês
10.1097/jcp.0000000000000800
ISSN1533-712X
AutoresLia Lira Olivier Sanders, Carlos Eduardo de Souza Menezes, Adriano José Maia Chaves Filho, Glautemberg de Almeida Viana, Francisco Vagnaldo Fechine, Maria Goretti Rodrigues de Queiroz, Said Gonçalvez da Cruz Fonseca, Silvânia Maria Mendes Vasconcelos, Maria Elisabete Amaral de Moraes, Clarissa Severino Gama, Sheila E.J. Seybolt, Eugênio de Moura Campos, Danielle S. Macêdo, David Freitas de Lucena,
Tópico(s)Bipolar Disorder and Treatment
ResumoAbstract Purpose/Background Accumulating evidence suggests an involvement of oxidative stress in the pathophysiology of schizophrenia. This offers a hypothesis-derived therapeutic approach to hinder oxidative damage and its clinical sequelae. α-Lipoic acid (ALA) is a powerful natural antioxidant indicated to treat diabetic neuropathy. Methods/Procedures In this pilot investigation, we administered ALA (100 mg/d) for 4 months, as an adjunct to antipsychotic medication, to 10 patients with schizophrenia. Findings/Results We found robust improvement in measures of psychopathology (63.9% reduction in Brief Psychiatric Rating Scale scores), neurocognitive parameters, extrapyramidal symptoms, and decreased lipid peroxidation. Implications/Conclusions If larger, double-blind, placebo-controlled studies confirm these preliminary findings, ALA could prove useful as adjunctive therapy for schizophrenia.
Referência(s)